Definition

IDSA and Surgical Infection Society define complicated intra-abdominal infection as infection extending beyond the hollow viscus of origin into the peritoneal space that is associated with abscess formation or peritonitis.

Risk factors for source control failure

• •
  

  Delay in treatment (>24 h)

  
  
• •
  

  High severity of illness (Acute Physiology and Chronic Health Evaluation II score ≥15)

  
  
• •
  

  Age >70 years

  
  
• •
  

  Medical comorbidity

  
  
• •
  

  Degree of organ dysfunction

  
  
• •
  

  Low albumin

  
  
• •
  

  Poor nutritional status

  
  
• •
  

  Degree of peritoneal involvement or diffuse peritonitis

  
  
• •
  

  Inability to achieve adequate debridement or drainage

  
  
• •
  

  Malignancy

Pathogens in order of prevalence

• •
  

  Escherichia coli

  
  
• •
  

  Bacteroides species

  
  
• •
  

  Streptococcus species

  
  
• •
  

  Clostridium species

  
  
• •
  

  Peptostreptococcus species, Eubacterium species

  
  
• •
  

  Klebsiella species, Pseudomonas aeruginosa

  
  
• •
  

  Prevotella species, Enterococcus faecalis

Treatment

• •
  

  Antibiotic regimen ( Table 10.1 )

  
  
  
  

  Table 10.1

  
  

  Empiric Antibiotic Therapy for Complicated Intra-Abdominal Infection

  
  

  Adapted from Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis . 2010;50(12): 133–164.

  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  TYPE OF INFECTION	ANTIBIOTIC REGIMEN
  Community-Acquired Extra-Biliary Intra-Abdominal Infection
  Mild-moderate severity	Cefoxitin Ertapenem Moxifloxacin Tigecycline Ticarcillin-clavulanic acid (unavailable in U.S.) Cefazolin + metronidazole Cefuroxime + metronidazole Ceftriaxone + metronidazole Cefotaxime + metronidazole Ciprofloxacin a + metronidazole Levofloxacin a + metronidazole
  High severity	Imipenem-cilastatin Meropenem Doripenem Piperacillin-tazobactam Cefepime + metronidazole Ceftazidime + metronidazole Ciprofloxacin a + metronidazole Levofloxacin a + metronidazole
  Biliary Intra-Abdominal Infection
  Community-acquired acute cholecystitis of mild to moderate severity	Cefazolin Cefuroxime Ceftriaxone
  Community-acquired acute cholecystitis of high severity or acute cholangitis following bilio-enteric anastomosis	Imipenem-cilastatin Meropenem Doripenem Piperacillin-tazobactam Cefepime + metronidazole Ciprofloxacin a + metronidazole Levofloxacin a + metronidazole
  Health care–associated biliary infection	Vancomycin plus one of the following: • Imipenem-cilastatin • Meropenem • Doripenem
  	• Piperacillin-tazobactam • Cefepime + metronidazole • Ciprofloxacin a + metronidazole • Levofloxacin a + metronidazole
  Health Care–Associated Intra-Abdominal Infection
  <20% resistant Pseudomonas aeruginosa , ESBL-producing Enterobacteriaceae , Acinetobacter , or other MDR GNB	Imipenem-cilastatin Meropenem Doripenem Piperacillin-tazobactam Cefepime + metronidazole Ceftazidime + metronidazole
  ESBL-producing Enterobacteriaceae , Pseudomonas aeruginosa >20% resistant to ceftazidime	Imipenem-cilastatin Meropenem Doripenem Piperacillin-tazobactam Aminoglycoside
  MRSA	Vancomycin

   
  

  ESBL , Extended-spectrum β-lactamase; GNB , Gram-negative bacilli; MDR , Multidrug resistant; MRSA , Methicillin-resistant Staphylococcus aureus

  
  

  a Recommend reviewing local population susceptibility reports given increasing resistance of Escherichia coli to fluoroquinolones

  
  
  
  
• •
  

  Antibiotic dosing ( Table 10.2 )

  
  
  
  

  Table 10.2

  
  

  Antibiotic Dosing for Complicated Intra-Abdominal Infection

  
  

  Data from Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis . 2010;50(12):133–164.

  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  ANTIBIOTIC	STANDARD DOSE (IV)	RENAL DOSING	COMMENTS
  Β-Lactam/β-Lactamase Inhibitor Combination
  Piperacillin-tazobactam	Non-PSA: 3.375 g q6h PSA: 4.5 g q6h	Non-PSA: CrCl 20–40: 2.25 g q6h CrCl <20: 2.25 g q8h HD: 2.25 g q12h a PSA: CrCl 20–40: 3.375 g q6h CrCl <20: 2.25 g q6h HD: 2.25 g q8h a	Off-label extended infusion: 3.375–4.5 g ×1 over 30 min, followed 4 h later by 4 h infusion q8h
  Carbapenems (Cross-Sensitivity With PCN Allergy)
  Doripenem	500 mg q8h	CrCl 30–50: 250 mg q8h CrCl 11–29: 250 mg q12h HD: 250 mg q24h a ; If PSA, 500 mg q12h ×1 then 500 mg 24 h a	Similar spectrum of activity as meropenem except more potent in vitro activity against PSA than meropenem
  Ertapenem	1 g q24h	CrCl ≤30 and HD: 500 mg daily	Compared to imipenem or meropenem, less active against PSA, Acinetobacter , enterococci , and PCN-resistant pneumococci
  Imipenem-cilastatin	500 mg q6h or 1 g q8h	CrCl 60–89: 500 mg q6h CrCl 30–59: 500 mg q8h CrCl 15–29 and HD: 500 mg q12h a CrCl <15 without HD: avoid use	Consider decreasing dose in patients <70 kg to prevent seizures
  Meropenem	1 g q8h	CrCl 26–50: same dose q12h CrCl 10–25: half dose q12h CrCl <10: half dose q24h HD: 500 mg q24h a	Similar spectrum of activity as imipenem; slightly lower risk of seizures than imipenem
  Cephalosporins (10% Cross-Sensitivity With PCN Allergy)
  Cefazolin	1–2 g q8h	CrCl 11–34: 50% dose q12h CrCl ≤10 and HD: 50% dose q24h a	—
  Cefepime	2 g q8–12h	CrCl 30–60: 2 g q12–24h CrCl <30: 1–2 g q24h HD: 0.5–1 g q24h a	Risk of seizures in renal insufficiency
  Cefotaxime	2 g q8h	CrCl <20: 50% dose q8h HD: 1–2 g q24h a	—
  Cefoxitin	2 g q6h	CrCl 30–50: 2 g q8–12h CrCl 10–29: 2 g q12–24h CrCl 5–9: 2 g ×1 then 1 g q12–24h CrCl <5 and HD: 2 g ×1 then 1 g q24–48h a	—
  Ceftazidime	2 g q8h	CrCl 31–50: 2 g q12h CrCl 16–30: 2 g q24h CrCl ≤15 and HD: 1 g q24h a	Possible cross-sensitivity between aztreonam and ceftazidime (<5%); avoid aztreonam if history of life-threatening reaction or anaphylaxis to ceftazidime. Other cephalosporins do not have the same risk as ceftazidime
  Ceftriaxone	2 g q24h	—	—
  Cefuroxime (Zinacef)	1.5 g q8h	CrCl 10–20: 1.5 g q12h CrCl <10 and HD: 1.5 g q24h a	—
  Ceftazidime 2 g-avibactam 0.5 g (Avycaz 2.5 g)	2.5 g q8h	CrCl 31–50: 1.25 g q8h CrCl 16–30: 0.94 g q12h CrCl 6–15: 0.94 g q24h CrCl ≤5 and HD: 0.94 g q48h a	Reserve for MDR PSA, and ESBL- and KPC-producing Enterobacteriaceae. Combine with metronidazole
  Ceftolozane 1 g-tazobactam 0.5 g (Zerbaxa 1.5 g)	1.5 g q8h	CrCl 30–50: 750 mg q8h CrCl 15–29: 375 mg q8h CrCl <15: not studied HD: 750 mg ×1 then 150 mg q8h a	Reserve for MDR PSA and ESBL-producing Enterobacteriaceae. Combine with metronidazole
  Glycylcycline
  Tigecycline	100 mg ×1 then 50 mg q12h	—	Increase in all-cause mortality observed in meta-analysis of Phase 3 and 4 clinical trials where greatest differences seen with ventilator-associated pneumonia
  Fluoroquinolones
  Ciprofloxacin	400 mg q12h	CrCl 5–29 and HD: 400 mg q24h a	ADR: tendonitis/tendon rupture, CNS effects, peripheral neuropathy, hepatotoxicity, crystalluria, photosensitivity, QT prolongation. CI: myasthenia gravis, children due to musculoskeletal toxicity
  Levofloxacin	750 mg q24h	CrCl 20–49: 750 mg q48h CrCl 10–19: 750 mg ×1, then 500 mg q48h HD: 750 mg ×1, then 500 mg q48h a	“
  Moxifloxacin	400 mg q24h	—	“
  Nitroimidazole
  Metronidazole	500 mg q8h	Give post HD on HD days	—
  Aminoglycosides
  Gentamicin or tobramycin	5–7 mg/kg q24h b	CrCl 20–60: 5–7 mg/kg q36–48 h b CrCl <20 and HD: 1–2.5 mg/kg LD, then based on level a , c	Consult pharmacist for dosing. Goal for once daily dosing: refer to Hartford nomogram d . Use adjusted BW for obese
  Amikacin	15–20 mg/kg q24h b	CrCl 20–60: 15–20 mg/kg q36–48h b CrCl <20 and HD: 5 mg/kg LD then based on level a , c	“
  Monobactam
  Aztreonam	1–2 g q6–8h	CrCl 10–30: 0.5–1 g q6–8h CrCl <10: 250–500 mg q6–8h HD: 1–2 g LD, then 250–500 mg q6–8h a	Possible cross-sensitivity between aztreonam and ceftazidime (<5%); see comment on ceftazidime
  Glycopeptide
  Vancomycin	15–20 mg/kg q8–12h	CrCl 15–50: 750–1500 mg q24h Max: 2 g/dose CrCl <15: 750–1500 mg based on level HD: 500–1000 mg based on level a	Consult pharmacist for dosing Goal trough: 10–15 mcg/mL (15–20 mcg/mL if visceral abscesses) Use actual BW for obese
  Notes: • Surgical management is critical in most intra-abdominal infections • 4–5 days is the recommended duration who have adequate source control; longer duration is appropriate if inadequate or uncertain source control
  • Empiric antifungal may be considered for upper gastrointestinal perforations, recurrent bowel perforations, surgically treated pancreatitis, heavy colonization with Candida species, or presence of yeast on intra-abdominal cultures • Candida albicans : Fluconazole IV 800 mg ×1 then 400 mg daily • Fluconazole-resistant Candida species: • Anidulafungin IV 200 mg ×1 then 100 mg daily • Caspofungin IV 70 mg ×1 then 50 mg daily • Micafungin IV 100 mg daily • Antienterococcal therapy: consider in postoperative infection, those who have previously received cephalosporins or other antimicrobial agents selecting for Enterococcus species, immunocompromised patients, and those with valvular heart disease or prosthetic intravascular materials • Anti-MRSA therapy: consider in patients with MRSA or MDRO risk factors (advanced age, comorbid medical conditions, previous hospitalization/surgery, recent antibiotic agents)

  Only gold members can continue reading. Log In or Register to continue

  Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

  Related

  Related posts:

  Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) Sepsis and septic shock Other neurocritical care Status epilepticus Fluids and electrolyte disorders Rapid sequence induction

  

  Stay updated, free articles. Join our Telegram channel

  Join